Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory chronic graft-versus-host disease

Yibo Wu, Lizhen Liu, Yi Chen, Xiaoyu Lai, Ying Lu, Luxin Yang, Lin Li, Lan Sun, Junjie Cao, Jimin Shi, Xiaolin Yuan, Panpan Zhu, He Huang, Yi Luo

Blood (2025) 146 (Supplement 1): 7761.

https://doi.org/10.1182/blood-2025-7761

Published: 2025

Journal Articles

Enhanced FLI1 accessibility mediates STAG2-mutant leukemogenesis

Blood (2025) 146 (Supplement 1): 1467.

https://doi.org/10.1182/blood-2025-1467

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood (2025) 146 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2025-3587

Published: 2025

Journal Articles

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Jennifer Woyach, Danielle Brander, Boyu Hu, Kerry Rogers, Zulfa Omer, Emily Curran, Deborah Stephens, Andrea Sitlinger, Yi Chen, Stephen Anthony, Yu Chen, Kewei Shang, John Byrd

Blood (2025) 146 (Supplement 1): 87.

https://doi.org/10.1182/blood-2025-87

Published: 2025

Journal Articles

STAG2 mutation preserves a stem cell phenotype in FLT3-ITD-mediated MDS to leukemia transformation

Jane J Xu, Yi Chen, John Pantazi, Sebastian Fernando, Besmira Alija, Varun Sudunagunta, Robert Bowman, Aaron Viny

Blood (2025) 146 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2025-3242

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia

Nanfang Zhuo, Fujie Shi, Xiangjie Lin, Pengfei Chai, Jianai Sun, Nianci Chen, Yi Chen, Jin Lei, Wenxiang Zhao, Jie Jin, Yinghui Zhu, Huafeng Wang

Blood (2025) 146 (Supplement 1): 2355.

https://doi.org/10.1182/blood-2025-2355

Published: 2025

Journal Articles

Stratos: An AI-driven biomarker signature for prognostic risk stratification in transplant-associated thrombotic microangiopathy - a nationwide, multicenter study

Blood (2025) 146 (Supplement 1): 120.

https://doi.org/10.1182/blood-2025-120

Published: 2025

Journal Articles

Divergence in post-traumatic stress disorder status between children receiving hematopoietic stem cell transplantation and their primary caregivers

Jiali Ma, Lijuan Liu, Jing Yao, Li Sun, Han Zhang, Yi Chen, Binghua Zhang

Blood (2025) 146 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2025-4268

Published: 2025

Journal Articles

Thioguanine and decitabine can overcome hypomethylating agent resistance in patients with advanced myeloid malignancies

Sunil Iyer, Joseph Jurcic, Daniel Lee, Mark Frattini, Monica Kasbekar, Alina Varabyeva, Azra Raza, Yi Chen, Rongjia Deng, Sebastian Fernando, Stefan Petkov, Simon Fredriksson, Aaron Viny, Todd Rosenblat

Blood (2025) 146 (Supplement 1): 3462.

https://doi.org/10.1182/blood-2025-3462

Published: 2025

Journal Articles

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Blood (2025) 146 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2025-1532

Published: 2025

Journal Articles

Investigating suspected germline STAG2 variants in myeloid neoplasms

Eno-obong Udoh, Yi Chen, Matteo D'Addona, Felipe de Almeida Sartori, Serhan Unlu, Zachary Brady, Jaroslaw Maciejewski, Valeria Visconte, Aaron Viny

Blood (2025) 146 (Supplement 1): 5609.

https://doi.org/10.1182/blood-2025-5609

Published: 2025

Journal Articles

Longitudinal single-cell spatial proteomics reveals predictive immune and stem cell signatures in Relapsed/Refractory AML

Varun Sudunagunta, Stefan Petkov, Rongjia Deng, Yi Chen, Sebastian Fernando, Edna Stewart, Michele Simonetti, Sunil Iyer, Monica Kasbekar, Daniel Lee, Mark Frattini, Simon Fredriksson, Joseph Jurcic, Todd Rosenblat, Aaron Viny

Blood (2025) 146 (Supplement 1): 1696.

https://doi.org/10.1182/blood-2025-1696

Published: 2025

Journal Articles

Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome

Varun Sudunagunta, Edna Stewart, Yi Chen, Hongxia Yan, Sebastian Fernando, Viviana Scoca, Jane J Xu, Mohandas Narla, Aaron Viny

Blood (2025) 146 (Supplement 1): 968.

https://doi.org/10.1182/blood-2025-968

Published: 2025

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2024-212040

Published: 2024

Journal Articles

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2024-203522

Published: 2024

Journal Articles

Stag2 Loss Drives Abnormal Chromatin Remodeling with Fli1 Hyperactivity in Npm1c Leukemia

Jane J. Xu, Viviana Scoca, Yi Chen, John Pantazi, Sebastian Fernando, Besmira Alija, Varun S. Sudunagunta, Aaron D. Viny

Blood (2024) 144 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2024-211064

Published: 2024

Journal Articles

Enhancing CAR T Cell Efficacy By Modulating PI3K Signaling Via a Synthetic CD28 Rheostat

Sanam Shahid, Winson Cai, Erin R. Burns, Jasmine S. Um, Serena Mathew, Sydney Souness, Sarah Yoo, Bing-Yi Chen, Takeshi Fujino, Renier Brentjens, Anthony F. Daniyan

Blood (2024) 144 (Supplement 1): 4802.

https://doi.org/10.1182/blood-2024-209964

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory chronic graft-versus-host disease

Enhanced FLI1 accessibility mediates STAG2-mutant leukemogenesis

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

STAG2 mutation preserves a stem cell phenotype in FLT3-ITD-mediated MDS to leukemia transformation

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia

Stratos: An AI-driven biomarker signature for prognostic risk stratification in transplant-associated thrombotic microangiopathy - a nationwide, multicenter study

Divergence in post-traumatic stress disorder status between children receiving hematopoietic stem cell transplantation and their primary caregivers

Thioguanine and decitabine can overcome hypomethylating agent resistance in patients with advanced myeloid malignancies

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Investigating suspected germline STAG2 variants in myeloid neoplasms

Longitudinal single-cell spatial proteomics reveals predictive immune and stem cell signatures in Relapsed/Refractory AML

Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Stag2 Loss Drives Abnormal Chromatin Remodeling with Fli1 Hyperactivity in Npm1c Leukemia

Enhancing CAR T Cell Efficacy By Modulating PI3K Signaling Via a Synthetic CD28 Rheostat

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only